HUB Organoids Launches IntegriGut Screen: A Breakthrough Service Offering for Inflammatory Bowel Disease (IBD) Drug Discovery and Development
HUB Organoids official news RSS · Indexed industry source record · Source published: Wed Jan 24 2024 17:36:01 GMT+0000 (Coordinated Universal Time) · Indexed here: Thu Oct 08 2026 07:03:32 GMT+0000 (Coordinated Universal Time)
Saved source excerpt
Utrecht, Netherlands – 25th Jan 2024 – HUB Organoids (HUB), a global leader and sole proprietor of patient-derived organoid technology for drug discovery and development, today announced the global launch of its new IntegriGut Screen. This innovative screening service employs IBD patient-derived organoid monolayers (PDO Monolayers) allowing access to high-quality human data on epithelial barrier [
This is a cited excerpt from the source. Read the original link for the complete text. Automated indexing and topic classification do not constitute fact verification.